Risperidone

Perseris, Risperdal, Risperdal Consta (risperidone) is a small molecule pharmaceutical. Risperidone was first approved as Perseris on 1993-12-29. It is used to treat autistic disorder, bipolar disorder, dementia, schizophrenia, and schizophrenia spectrum and other psychotic disorders amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D. In addition, it is known to target D(3) dopamine receptor, alpha-1A adrenergic receptor, 5-hydroxytryptamine receptor 1E, alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2C, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, histamine H1 receptor, 5-hydroxytryptamine receptor 1F, and e Lysozyme murein hydrolase. Risperdal's patents are valid until 2028-02-13 (FDA).